Breaking: FDA confirms Eli Lilly's obesity drug shortage is over

The agency said it would give compounders a grace period of 60 to 90 days before enforcing rules that would put a halt to their work

Log In    Subscribe BREAKING NEWS   FDA confirms tirzepatide shortage is over, gives compounders a grace period By Elaine Chen Rick Berke / STAT The FDA confirmed today that a shortage of Eli Lilly's obesity drug tirzepatide has been resolved, a move that will soon put a stop to companies making cheaper copies of the injection. The decision could set a precedent for how the agency handles Novo Nordisk's semaglutide, which may be close to coming off the shortage list. READ MORE Sign up for The Readout Your morning rundown of the science, politics, and money driving biotech today. Learn more. In Case You Missed It 1   Eli Lilly to test obesity medications as treatments for alcohol and drug addiction, CEO says By Elaine Chen 2   2025's looking like the year of chronic disease. Here are three issues to watch By Elizabeth Cooney and Isabella Cueto 3   Truth-teller or reflexive contrarian: Which Marty Makary would run the FDA? By Lizzy Lawrence 4   Worst Biopharma CEO of 2024? It's no contest By Adam Feuerstein Don't miss out on another STAT Investigation Unlock the world of health and medicine with a subscription to STAT+ Learn more STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us